<SEC-DOCUMENT>0001070081-20-000127.txt : 20200805
<SEC-HEADER>0001070081-20-000127.hdr.sgml : 20200805
<ACCEPTANCE-DATETIME>20200805160611
ACCESSION NUMBER:		0001070081-20-000127
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20200805
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200805
DATE AS OF CHANGE:		20200805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PTC THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001070081
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043416587
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35969
		FILM NUMBER:		201077266

	BUSINESS ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449
		BUSINESS PHONE:		9082227000

	MAIL ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTC THERAPEUTICS INC
		DATE OF NAME CHANGE:	19980909
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a8k8520.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:C35A510AD79A5683B804DE18236B44F9,x:a5faf9a7aae94aadac9cdeea15ad7f03-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2020 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:ptct="http://www.ptcbio.com/20200805" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="D2020Q3E" name="dei:AmendmentFlag" id="Fact-4F979432D305596D913B7EBE8879AB76-wk-Fact-4F979432D305596D913B7EBE8879AB76" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="D2020Q3E" name="dei:EntityCentralIndexKey" id="Fact-0D0EC0B070A95DF5B791286A427089C2-wk-Fact-0D0EC0B070A95DF5B791286A427089C2">0001070081</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="ptct-20200805.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="D2020Q3E">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-08-05</xbrli:startDate>
			<xbrli:endDate>2020-08-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context></ix:resources></ix:header></div><div><a id="s5D19BE012F0B5C368F350CADA3CF95EE"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">WASHINGTON, D.C. 20549</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM </span><span><ix:nonNumeric id="d13084735e67-wk-Fact-68499F752497548E85B143C712605F12" name="dei:DocumentType" contextRef="D2020Q3E"><span style="font-size:18pt;font-weight:bold;">8-K</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:18pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date of Report (Date of earliest event reported):  </span><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d13084735e81-wk-Fact-33EFA30D7C555A7DBAAA3718951FE2DE" name="dei:DocumentPeriodEndDate" contextRef="D2020Q3E" format="ixt:datemonthdayyearen">August 5, 2020</ix:nonNumeric></span></span></span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:18pt;"><span><ix:nonNumeric id="d13084735e86-wk-Fact-94A86FC750FE5F92BCB30AA98F234082" name="dei:EntityRegistrantName" contextRef="D2020Q3E"><span style="font-size:18pt;font-weight:bold;">PTC THERAPEUTICS, INC.</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:18pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Exact Name of Company as Specified in Charter)</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:677px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:214px;"></td><td style="width:16px;"></td><td style="width:214px;"></td><td style="width:16px;"></td><td style="width:214px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d13084735e110-wk-Fact-BB8366D61231524CAEDC7DBC8310A572" name="dei:EntityIncorporationStateCountryCode" contextRef="D2020Q3E" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d13084735e120-wk-Fact-32E5B10931A651388AD71E73573CAC6C" name="dei:EntityFileNumber" contextRef="D2020Q3E">001-35969</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d13084735e130-wk-Fact-67611E6ECD225CD6AC00C60F0A34FC02" name="dei:EntityTaxIdentificationNumber" contextRef="D2020Q3E">04-3416587</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(State or Other Jurisdiction</span></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of Incorporation)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Commission</span></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">File Number)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(IRS Employer</span></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identification No.)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:517px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:141px;"></td><td style="width:114px;"></td><td style="width:33px;"></td><td style="width:228px;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d13084735e182-wk-Fact-5057FCCA38D554CB97E84E8CBAE55E79" name="dei:EntityAddressAddressLine1" contextRef="D2020Q3E">100 Corporate Court</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d13084735e203-wk-Fact-97AB5057C3075063A87EC7385A15593C" name="dei:EntityAddressCityOrTown" contextRef="D2020Q3E">South Plainfield,</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d13084735e208-wk-Fact-088FC68F16FE5B3A9468247F1DCBCFDE" name="dei:EntityAddressStateOrProvince" contextRef="D2020Q3E">NJ</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d13084735e218-wk-Fact-D0F3DB3658265DD5AE4C5ADD58C49C8B" name="dei:EntityAddressPostalZipCode" contextRef="D2020Q3E">07080</ix:nonNumeric></span></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Address of Principal Executive Offices)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Zip Code)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Registrant&#8217;s telephone number, including area code: </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d13084735e245-wk-Fact-62A845CCE640584D8AA8006CC0285511" name="dei:CityAreaCode" contextRef="D2020Q3E">(908)</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d13084735e249-wk-Fact-5B92A3BBFF4E5E02BB6B6116F0079635" name="dei:LocalPhoneNumber" contextRef="D2020Q3E"><span style="font-weight:bold;">222-7000</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Not applicable</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">see</span><span style="font-family:inherit;font-size:10pt;"> General Instruction A.2. below):</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span><ix:nonNumeric id="d13084735e270-wk-Fact-F89F470AF7EB57F59FB8DFC3F3743B3E" name="dei:WrittenCommunications" contextRef="D2020Q3E" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:5pt;">    </span><span style="font-family:inherit;font-size:10pt;"> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span><ix:nonNumeric id="d13084735e280-wk-Fact-A9E59E4F8EF15CC884D91487C5D578E0" name="dei:SolicitingMaterial" contextRef="D2020Q3E" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:5pt;">    </span><span style="font-family:inherit;font-size:10pt;"> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span><ix:nonNumeric id="d13084735e290-wk-Fact-AF64783EB25350B38E09F4F55D4F4A8B" name="dei:PreCommencementTenderOffer" contextRef="D2020Q3E" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:5pt;">    </span><span style="font-family:inherit;font-size:10pt;"> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span><ix:nonNumeric id="d13084735e300-wk-Fact-3CCF5084961553B8A911A2258BAF507B" name="dei:PreCommencementIssuerTenderOffer" contextRef="D2020Q3E" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:5pt;">    </span><span style="font-family:inherit;font-size:10pt;"> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:41%;"></td><td style="width:18%;"></td><td style="width:41%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Trading Symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d13084735e342-wk-Fact-3694E7541D0E5E5E9D7ED50ADD2285E0" name="dei:Security12bTitle" contextRef="D2020Q3E">Common Stock, $0.001 par value per share</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d13084735e347-wk-Fact-917658A6465A54EBAA7FDEE6BB071639" name="dei:TradingSymbol" contextRef="D2020Q3E">PTCT</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d13084735e352-wk-Fact-E45F2088156C54848A32499CD123C127" name="dei:SecurityExchangeName" contextRef="D2020Q3E" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging growth company&#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d13084735e362-wk-Fact-0CD23217F7935AED8E15789DBA0D8BE0" name="dei:EntityEmergingGrowthCompany" contextRef="D2020Q3E" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;  </span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><a id="sEBA3FC715C4053D1993CC775F386E0AA"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2.02. &#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 5, 2020, PTC Therapeutics, Inc. (the &#8220;Company&#8221;) announced its financial results for the quarter ended June 30, 2020. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Report") and is incorporated by reference into this Item 2.02.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7.01. Regulation FD Disclosure.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company will host a conference call on August 5, 2020 at 4:30 PM eastern time, as previously announced. During this call the Company expects to review financial results for the quarter ended June 30, 2020, as well as other corporate highlights and updates.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Directions on how to access the conference call are included in the press release furnished as Exhibit 99.1 hereto.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information in this Report (including Items 2.02 and 7.01 and Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the&#160;Securities Act of 1933, as amended, or the&#160;Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01. </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Statements and Exhibits.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(d) Exhibits</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.8984375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:17%;"></td><td style="width:6%;"></td><td style="width:77%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit No.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">99.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ptctq2earningsrelease8.htm"><span style="font-family:inherit;font-size:10pt;">Press Release, dated August 5, 2020 issued by PTC Therapeutics, Inc.</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">104</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Signature</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:56%;"></td><td style="width:6%;"></td><td style="width:38%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PTC Therapeutics, Inc.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date: August 5, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">By:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Emily Hill</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Name:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emily Hill</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Title:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chief Financial Officer</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div>	</div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ptctq2earningsrelease8.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sAD16B4FF1518C95AF50ABFCAB4456DAC"></a></div><div><div style="line-height:120%;text-align:right;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"></font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EXHIBIT 99.1</font></div><div style="line-height:120%;text-align:left;"><img src="ptctq2earningsrelease_image1.gif" alt="ptctq2earningsrelease_image1.gif" style="height:94px;width:156px;"></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">PTC Therapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate Update</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">- Strong Emflaza</font><font style="font-family:Arial;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#32;2Q 2020 performance with 30% YoY net product revenue increase &#8211;</font></div><div style="line-height:120%;text-align:center;padding-left:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">- Initiated PTC299 trial in COVID-19 in multiple countries &#8211;</font></div><div style="line-height:120%;text-align:center;padding-left:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">- Initiated clinical trial with PTC857, identified from Bio-e platform &#8211;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">- Greater than $1B in cash to accelerate pipeline growth &#8211; </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">SOUTH PLAINFIELD, N.J., August 5, 2020</font><font style="font-family:Arial;font-size:10pt;">&#32;&#8211; PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the second quarter ending June 30, 2020. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8220;We are pleased with the progress in our pipeline and the strong commercial performance of our global Duchenne franchise,&#8221; said Stuart W. Peltz, Ph.D., CEO of PTC Therapeutics. &#8220;Our growing revenue stream allows us to continue to invest in the development of treatments leveraging our novel technology platforms. We have a robust pipeline and with more than $1 billion in cash are well positioned to advance multiple differentiated therapies for patients living with rare disorders, not only in the near term, but also for many years to come.&#8221; </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Key Second Quarter and Other Corporate Updates: </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;">Our Duchenne muscular dystrophy franchise had strong performance in the second quarter. The greater than 30% year-over-year increase in second quarter sales for Emflaza was driven by ongoing improvements in our commercial business. New Duchenne patients continue to be identified in Europe, LATAM and other key markets for Translarna</font><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;"><sup style="vertical-align:top;line-height:120%;background-color:#ffffff; font-size:6pt">&#8482;</sup></font><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;">&#32;despite the challenges of COVID-19. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As part of the annual renewal process for Translarna, the European Medicines Agency (EMA) confirmed its risk/benefit profile for the sixth consecutive year. In addition, PTC previously announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA recommended to remove the statement "efficacy has not been demonstrated in non-ambulatory patients" from the SmPC for Translarna. This label change enables healthcare professionals to use their clinical judgement to make treatment decisions for their patients on Translarna who have lost ambulation and should support reimbursement agencies granting continued access to Translarna. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the second quarter, PTC strengthened its pipeline and platforms with the acquisition of a late-stage asset for phenylketonuria (PKU). PTC923 is a clinical-stage investigational therapy for inborn errors of metabolism, including PKU and other diseases associated with defects in the tetrahydrobiopterin (BH4) biochemical pathways diagnosed at birth. PTC is currently conducting nonclinical studies to support the long-term dosing for the planned phase 3 trial in PKU in 2021.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The U.S. Food and Drug Administration (FDA) PDUFA date for risdiplam is August 24, 2020. In addition, a submission of a marketing authorization application (MAA) to EMA for risdiplam is imminent. The filing of the MAA would trigger a $15 million milestone payment to PTC from Roche. Roche has submitted applications for approval in Brazil, Chile, China, Indonesia, Russia, South Korea and Taiwan. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PTC recently announced an agreement to monetize a portion of the rights to the risdiplam royalty stream for a $650 million up front payment from Royalty Pharma plc, providing PTC with significant non-dilutive capital. PTC retains nearly 60% of the risdiplam royalty stream up until a $1.3 billion threshold is reached, after which PTC retains 100% of the risdiplam royalty stream. PTC also retains all economics associated with up to approximately $400 million in remaining regulatory and sales milestones. </font></div></td></tr></table><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;"><img src="ptctq2earningsrelease_image1.gif" alt="ptctq2earningsrelease_image1.gif" style="height:94px;width:156px;"></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Launch activities for Tegsedi</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174; </sup></font><font style="font-family:Arial;font-size:10pt;">continue to focus on patient finding. Pricing discussions in Brazil are ongoing and are expected to be completed by the end of the year.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The submission of an application for marketing authorization for Waylivra</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;in patients with familial chylomicronemia syndrome (FCS) has been filed with ANVISA and a decision is expected in 2021. Patient finding and early access programs are ongoing.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PTC continues to develop manufacturing capabilities for its gene therapy products. It has expanded its collaboration with MassBiologics for the manufacturing of the aromatic L-amino acid decarboxylase deficiency (AADCd) commercial supply. In addition, PTC gained occupancy under its lease of ~220,000 square feet at the former BMS site in Hopewell, NJ. Manufacturing of clinical materials for its gene therapy programs at this site is expected to initiate in 2021. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PTC recently launched a global internship program, the Talent Pipeline Program (TPP), aimed at providing recent graduates, especially those in minority communities, with real-world experience in the biopharmaceutical industry and related professions, including research, finance, commercial, compliance, quality, legal, information technology, and communications. The TPP will provide approximately 30 interns with a one-year paid program with real-world training experience.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Updates in PTC's Diverse Product Pipeline</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In its Bio-e platform, PTC expects to initiate potential registrational trials with vatiquinone, formerly known as PTC743, in refractory mitochondrial epilepsy in the third quarter of 2020 and in Friedreich ataxia in the fourth quarter of 2020. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The first subject has been dosed in the Phase 1 trial for PTC857, PTC&#8217;s second compound from the Bio-e platform. Data from the single ascending dose and multiple ascending dose studies is expected by the end of 2020. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PTC recently initiated a Phase 2/3 clinical trial for PTC299 for COVID-19 called FITE-19. PTC expects Stage 1 to be completed in the second half of 2020 and anticipates reporting top-line results from both stages in the first half of 2021. Multiple sites have been opened in the U.S., Brazil, Spain and Australia with additional countries for Stage 2 expected to initiate in the coming months. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the novel splicing platform, the Huntington disease program remains on track for the initiation of first-in-human studies in 2020. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PTC expects to initiate submission of the biologics license application (BLA) to the U.S. FDA in the second half of 2020 for its AADCd gene therapy program.</font><font style="font-family:inherit;font-size:11pt;">&#32;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Due to COVID-19 related delays, PTC now expects the final opinion from the CHMP on the MAA for the AADCd program in the first quarter of 2021. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Given the evolving COVID-19 situation in the U.S., the final study muscle biopsies have not yet been collected from 8 remaining boys in the Translarna (ataluren) dystrophin study. PTC is continuously monitoring the situation to determine when it will be possible to safely obtain the final biopsies and is exploring all potential options in order to have a data read out by the end of 2020. All patients in the study remain on Translarna until they are able to complete the final study visit.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Financial Highlights:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;color:#333333;">Total net product revenues were</font><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;">&#32;$75.2 million across our commercial portfolio for the second quarter of 2020, compared to total net product revenues of $85.5 million for the second quarter of 2019. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;">Translarna net product revenues were $38.6 million for the second quarter of 2020, compared to $57.8 million for the second quarter of 2019. Revenues for the second quarter of 2020 were impacted by the timing of a group purchase order from Brazil, which is the primary driver for the year-over-year decrease, as the second quarter of 2019 included a significant group purchase order from Brazil. Due to the impact of the pandemic, there was an administrative delay by the </font></div></td></tr></table><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;"><img src="ptctq2earningsrelease_image1.gif" alt="ptctq2earningsrelease_image1.gif" style="height:94px;width:156px;"></div></div><div><br></div><div style="line-height:130%;padding-left:48px;text-align:left;"><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;">Brazilian Ministry of Health in receiving the centralized Translarna group purchase order. PTC anticipates a group purchase order from Brazil later this year.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Emflaza net product revenues were $36.2 million for the second quarter of 2020, compared to $27.6 million for the second quarter of 2019. Growth in net product revenues was driven by new patient prescriptions and continued operational improvements and efficiencies in our commercial business.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:10pt;">Generally accepted accounting principles in the U.S. (GAAP) research and development (R&amp;D) expenses were $176.5 million for the second quarter of 2020, compared to $60.0 million for the second quarter of 2019. The increase in R&amp;D expenses includes one-time charges of $53.6 million related to the acquisition of Censa Pharmaceuticals, and $41.2 million related to the MassBiologics of the University of Massachusetts Medical School agreement for commercial manufacturing of our lead gene therapy program in AADCd.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Non-GAAP R&amp;D expenses were $168.0 million for the second quarter of 2020, excluding $8.6 million in non-cash, stock-based compensation expense, compared to $54.5 million for the second quarter of 2019, excluding $5.5 million in non-cash, stock-based compensation expense.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">GAAP selling, general and administrative (SG&amp;A) expenses were $53.7 million for the second quarter of 2020, compared to $49.2 million for the second quarter of 2019. The increase reflects continued investment to support our commercial activities including our expanding commercial portfolio.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Non-GAAP SG&amp;A expenses were $45.3 million for the second quarter of 2020, excluding $8.3 million in non-cash, stock-based compensation expense, compared to $43.8 million for the second quarter of 2019, excluding $5.4 million in non-cash, stock-based compensation expense.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Change in the fair value of deferred and contingent consideration was $7.7 million for the second quarter of 2020, compared to $5.3 million for the second quarter of 2019. The change in fair value of deferred and contingent consideration is related to the fair valuation of potential future consideration to be paid to former equity holders of Agilis Biotherapeutics, Inc. (Agilis) in connection with PTC's acquisition of Agilis, which closed in August 2018.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:10pt;">Settlement of deferred and contingent consideration was $10.6 million for the second quarter of 2020. The settlement of deferred and contingent consideration is related to a loss upon the settlement of the deferred and contingent consideration liabilities as a result of the rights exchange agreement with certain former shareholders of Agilis, whereby such former shareholders exchanged their pro rata share of specific future cash milestone payments in the aggregate amount of $225 million for a mixture of cash and equity of PTC. Under this agreement, which the former shareholders and PTC entered into on April 29, 2020, PTC has paid $36.9 million in cash and issued 2,821,176 shares of common stock in exchange for the cancellation and forfeiture of the participating shareholders' rights to receive (i) $174.0 million, in the aggregate, of potential milestone payments based on the achievement of certain regulatory milestones and (ii) $37.6 million, in the aggregate, of $40.0 million in development milestone payments that would have been due upon the passing of the second anniversary of the closing of the Merger, regardless of whether the milestones are achieved.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net loss was $181.4 million for the second quarter of 2020, compared to net loss of $41.8 million for the second quarter of 2019.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash, cash equivalents and marketable securities were $498.9 million as of June 30, 2020, compared to $686.6 million as of December 31, 2019.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Shares issued and outstanding as of June 30, 2020 were 67,240,679.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:152%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Non-GAAP Financial Measures:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In this press release, the financial results of PTC are provided in accordance with GAAP and using certain non-GAAP financial measures. In particular, the non-GAAP financial measures exclude non-cash, stock-based compensation expense. These non-GAAP financial measures are provided as a complement to financial measures reported in GAAP because management uses these non-GAAP financial measures when assessing and identifying operational trends. In management's opinion, these non-GAAP financial </font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;"><img src="ptctq2earningsrelease_image1.gif" alt="ptctq2earningsrelease_image1.gif" style="height:94px;width:156px;"></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">measures are useful to investors and other users of PTC's financial statements by providing greater transparency into the historical and projected operating performance of PTC and the company's future outlook. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. Quantitative reconciliations of the non-GAAP financial measures to their respective closest equivalent GAAP financial measures are included in the table below.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;"><img src="ptctq2earningsrelease_image1.gif" alt="ptctq2earningsrelease_image1.gif" style="height:94px;width:156px;"></div></div><div><br></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:124%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PTC Therapeutics, Inc.</font></div><div style="line-height:124%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Operations</font></div><div style="line-height:124%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(In thousands, except share and per share data)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:3%;"></td><td style="width:2%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net product revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,239</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,476</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,435</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">138,530</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration and grant revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">575</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,239</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,522</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,498</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,105</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of product sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:10px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,304</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:10px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,211</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,389</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,587</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of acquired intangible asset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,731</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,575</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,679</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,652</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">176,525</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,979</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">266,632</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,544</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative (2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,659</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,215</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111,869</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,760</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in the fair value of deferred and contingent consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,680</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,300</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,580</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,460</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Settlement of deferred and contingent consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,613</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,613</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,512</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,280</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">423,762</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">247,003</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(187,273)</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,758)</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(280,264)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(107,898)</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,379)</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,074)</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,021)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,362)</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense), net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,309</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(183)</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,523)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(292)</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before income tax expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(181,343)</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(41,015)</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(293,808)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(112,552)</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(84)</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(774)</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(306)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,350)</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to common stockholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(181,427)</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(41,789)</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(294,114)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(113,902)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares outstanding:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted (in shares)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:10px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,150,780</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:10px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,912,748</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,769,958</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,113,141</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share&#8212;basic and diluted (in dollars per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.780)</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.750)</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4.610)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.990)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1) Research and development reconciliation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GAAP research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">176,525</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,979</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">266,632</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,544</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: share-based compensation expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:10px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,562</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:10px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,516</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,741</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:10px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,203</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-GAAP research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167,963</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,463</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">249,891</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,341</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(2) Selling, general and administrative reconciliation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GAAP selling, general and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,659</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,215</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111,869</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,760</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: share-based compensation expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:10px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,348</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:10px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,404</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,389</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:10px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,981</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-GAAP selling, general and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,311</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,811</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,480</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,779</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;"><img src="ptctq2earningsrelease_image1.gif" alt="ptctq2earningsrelease_image1.gif" style="height:94px;width:156px;"></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:124%;padding-bottom:10px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PTC Therapeutics, Inc.</font></div><div style="line-height:124%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary Consolidated Balance Sheets</font></div><div style="line-height:124%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in thousands, except share data)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:60%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2019</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">498,891</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">686,563</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,476,637</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,623,782</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:right;text-indent:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">315,362</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">313,859</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,702</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:right;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,657</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">904,143</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,029,452</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders' equity (67,240,679 and 61,935,870 common shares issued and outstanding at June 30, 2020 and December 31, 2019 respectively)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">572,494</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">594,330</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities and stockholders' equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,476,637</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,623,782</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;"><img src="ptctq2earningsrelease_image1.gif" alt="ptctq2earningsrelease_image1.gif" style="height:94px;width:156px;"></div></div><div><br></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Today's Conference Call and Webcast Reminder:</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Arial;font-size:10pt;">Today's conference call will take place at 4:30 pm (ET)&#160;and can be access by dialing (877) 303-9216 (domestic) or (973) 935-8152 (international) five minutes prior to the start of the call and providing the passcode 5897698. A live, listen-only webcast of the conference call can be accessed on the investor relations section of the PTC website at www.ptcbio.com. A webcast replay of the call will be available approximately two hours after completion of the call and will be archived on the company's website for</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Arial;font-size:10pt;">30 days following the call.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">About PTC Therapeutics, Inc.</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Arial;font-size:10pt;">PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">For More Information:</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Investors:</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Arial;font-size:10pt;">Alex Kane <br>+1 (908) 912-9643</font><font style="font-family:inherit;font-size:10pt;">&#32;<br>akane@ptcbio.com</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Media:</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Arial;font-size:10pt;">Jane Baj <br>+1 (908) 912-9167</font><font style="font-family:inherit;font-size:10pt;">&#32;<br>jbaj@ptcbio.com</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Forward Looking Statements: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses and other matters; expectations with respect to PTC's gene therapy platform, including any potential regulatory submissions and manufacturing capabilities; advancement of PTC's joint collaboration program in SMA, including any potential regulatory submissions, commercialization or royalty or milestone payments; PTC's expected use of proceeds from the agreement with Royalty Pharma; PTC's expectations with respect to the licensing, regulatory submissions and commercialization of its products and product candidates; the timing with respect to orders for PTC&#8217;s products; expectations with respect to the impacts of the COVID-19 pandemic and related response measures; PTC's strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC's products or product candidates that PTC commercializes or may commercialize in the future; expectations with respect to PTC's gene therapy platform, including any potential regulatory submissions </font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;"><img src="ptctq2earningsrelease_image1.gif" alt="ptctq2earningsrelease_image1.gif" style="height:94px;width:156px;"></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">and potential approvals, manufacturing capabilities and the potential financial impact and benefits of its leased biologics manufacturing facility and the potential achievement of development, regulatory and sales milestones and contingent payments that PTC may be obligated to make; the enrollment, conduct, and results of ongoing studies under the SMA collaboration and events during, or as a result of, the studies that could delay or prevent further development under the program, including any potential regulatory submissions and potential commercialization with respect to risdiplam; PTC's ability to complete a dystrophin study necessary to support a re-submission of its Translarna NDA for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) to the FDA, and PTC's ability to perform any necessary additional clinical trials, non-clinical studies, and CMC assessments or analyses at significant cost; PTC's ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in the European Economic Area (EEA), including whether the European Medicines Agency (EMA) determines in future annual renewal cycles that the benefit-risk balance of Translarna authorization supports renewal of such authorization; PTC's ability to enroll, fund, complete and timely submit to the EMA the results of Study 041, a randomized, 18-month, placebo-controlled clinical trial of Translarna for the treatment of nmDMD followed by an 18-month open-label extension, which is a specific obligation to continued marketing authorization in the EEA; expectations with respect to the commercialization of Tegsedi and Waylivra; the enrollment, conduct and results of PTC&#8217;s PTC299 clinical trial for COVID-19; expectations with respect to the COVID-19 pandemic and related response measures and their effects on PTC's business, operations, clinical trials, potential regulatory submissions and approvals, and PTC's collaborators, contract research organizations, suppliers and manufacturers; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC's products and product candidates; PTC's scientific approach and general development progress; PTC's ability to satisfy its obligations under the terms of the lease agreement for its leased biologics manufacturing facility; the sufficiency of PTC's cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the "Risk Factors" section of PTC's most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Translarna, Emflaza, risdiplam, Tegsedi, Waylivra or PTC-AADC.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ptct-20200805.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ptcbio.com/20200805" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ptct="http://www.ptcbio.com/20200805" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ptct-20200805_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ptct-20200805_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ptct-20200805_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ptct-20200805_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="CoverPageDocument" roleURI="http://www.ptcbio.com/role/CoverPageDocument">
        <link:definition>0001000 - Document - Cover Page Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="ptct_CoverpageAbstract" name="CoverpageAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>ptct-20200805_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.ptcbio.com/role/CoverPageDocument" xlink:href="ptct-20200805.xsd#CoverPageDocument" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/CoverPageDocument" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>ptct-20200805_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.ptcbio.com/role/CoverPageDocument" xlink:href="ptct-20200805.xsd#CoverPageDocument" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/CoverPageDocument" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>ptct-20200805_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_ptct_CoverpageAbstract_9F9EA1EE689BFAAE34CB12EB78562B6C_label_en-US" xlink:label="lab_ptct_CoverpageAbstract_F2AF802911AA504F9499C3278686FCED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">cover page [Abstract]</link:label>
    <link:label id="lab_ptct_CoverpageAbstract_9F9EA1EE689BFAAE34CB12EB78562B6C_documentation_en-US" xlink:label="lab_ptct_CoverpageAbstract_F2AF802911AA504F9499C3278686FCED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">cover page [Abstract]</link:label>
    <link:loc xlink:href="ptct-20200805.xsd#ptct_CoverpageAbstract" xlink:label="loc_ptct_CoverpageAbstract_F2AF802911AA504F9499C3278686FCED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_CoverpageAbstract_F2AF802911AA504F9499C3278686FCED" xlink:to="lab_ptct_CoverpageAbstract_F2AF802911AA504F9499C3278686FCED" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_C4517B94B84052FE32B512EB785B4079_terseLabel_en-US" xlink:label="lab_dei_DocumentType_9E7EE3083DD7584B8420EF40F0FF72BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_C4517B94B84052FE32B512EB785B4079_label_en-US" xlink:label="lab_dei_DocumentType_9E7EE3083DD7584B8420EF40F0FF72BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_9E7EE3083DD7584B8420EF40F0FF72BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_9E7EE3083DD7584B8420EF40F0FF72BC" xlink:to="lab_dei_DocumentType_9E7EE3083DD7584B8420EF40F0FF72BC" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_0E83231B49EC1FE81A3612EB785BBF36_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_CE7C9F6A10D55E9CAC5927881326C3B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_0E83231B49EC1FE81A3612EB785BBF36_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_CE7C9F6A10D55E9CAC5927881326C3B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_CE7C9F6A10D55E9CAC5927881326C3B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_CE7C9F6A10D55E9CAC5927881326C3B3" xlink:to="lab_dei_DocumentPeriodEndDate_CE7C9F6A10D55E9CAC5927881326C3B3" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_C596222BA97ACDF1A10B12EB785B6491_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_F69AA206B4DC5E13868DF2306B48F46A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_C596222BA97ACDF1A10B12EB785B6491_label_en-US" xlink:label="lab_dei_EntityRegistrantName_F69AA206B4DC5E13868DF2306B48F46A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_F69AA206B4DC5E13868DF2306B48F46A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_F69AA206B4DC5E13868DF2306B48F46A" xlink:to="lab_dei_EntityRegistrantName_F69AA206B4DC5E13868DF2306B48F46A" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_F7E76C8EB6B2A429763012EB785A74D9_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_771A8C419C8B5C9F997AFAD56B5220F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_F7E76C8EB6B2A429763012EB785A74D9_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_771A8C419C8B5C9F997AFAD56B5220F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_771A8C419C8B5C9F997AFAD56B5220F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_771A8C419C8B5C9F997AFAD56B5220F2" xlink:to="lab_dei_EntityIncorporationStateCountryCode_771A8C419C8B5C9F997AFAD56B5220F2" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_E7EA6DB36C0F561D720212EB7B8131CB_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_8F5DE1156E095CA49AF970255BEA3766" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contained File Information, File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_E7EA6DB36C0F561D720212EB7B8131CB_label_en-US" xlink:label="lab_dei_EntityFileNumber_8F5DE1156E095CA49AF970255BEA3766" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_8F5DE1156E095CA49AF970255BEA3766" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_8F5DE1156E095CA49AF970255BEA3766" xlink:to="lab_dei_EntityFileNumber_8F5DE1156E095CA49AF970255BEA3766" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_E3123AAC3A41E48A1A9712EB785C4170_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_CBB8F09B97255FAE88614683DE811FCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_E3123AAC3A41E48A1A9712EB785C4170_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_CBB8F09B97255FAE88614683DE811FCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_CBB8F09B97255FAE88614683DE811FCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_CBB8F09B97255FAE88614683DE811FCB" xlink:to="lab_dei_EntityTaxIdentificationNumber_CBB8F09B97255FAE88614683DE811FCB" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_DDE7C637B1DE93E587D112EB785A5F77_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_A1DCE45656CB5EF69D32FA2BB8C3C9BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_DDE7C637B1DE93E587D112EB785A5F77_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_A1DCE45656CB5EF69D32FA2BB8C3C9BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_A1DCE45656CB5EF69D32FA2BB8C3C9BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_A1DCE45656CB5EF69D32FA2BB8C3C9BA" xlink:to="lab_dei_EntityAddressAddressLine1_A1DCE45656CB5EF69D32FA2BB8C3C9BA" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_592048EF44AAE536846012EB785C0C8F_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_BBE78AB9F41A5CB09756FE0AF1F5C62E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_592048EF44AAE536846012EB785C0C8F_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_BBE78AB9F41A5CB09756FE0AF1F5C62E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_BBE78AB9F41A5CB09756FE0AF1F5C62E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_BBE78AB9F41A5CB09756FE0AF1F5C62E" xlink:to="lab_dei_EntityAddressCityOrTown_BBE78AB9F41A5CB09756FE0AF1F5C62E" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_D134AAF98F8970CE5DA412EB785C86A7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_3F350A39A7E556F184B683327E6B789A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_D134AAF98F8970CE5DA412EB785C86A7_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_3F350A39A7E556F184B683327E6B789A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_3F350A39A7E556F184B683327E6B789A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_3F350A39A7E556F184B683327E6B789A" xlink:to="lab_dei_EntityAddressStateOrProvince_3F350A39A7E556F184B683327E6B789A" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_3A88E27A4B92A3EB914412EB785C141A_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_9C7CB798F5DC511D8F1E93BBE1BF2874" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3A88E27A4B92A3EB914412EB785C141A_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_9C7CB798F5DC511D8F1E93BBE1BF2874" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_9C7CB798F5DC511D8F1E93BBE1BF2874" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_9C7CB798F5DC511D8F1E93BBE1BF2874" xlink:to="lab_dei_EntityAddressPostalZipCode_9C7CB798F5DC511D8F1E93BBE1BF2874" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_1AEC18E92172051E527C12EB785C731C_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_087588155CA15C37B5540C9F7B6803F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_1AEC18E92172051E527C12EB785C731C_label_en-US" xlink:label="lab_dei_CityAreaCode_087588155CA15C37B5540C9F7B6803F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_087588155CA15C37B5540C9F7B6803F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_087588155CA15C37B5540C9F7B6803F9" xlink:to="lab_dei_CityAreaCode_087588155CA15C37B5540C9F7B6803F9" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_5A3B1F056BEACDAA3FC312EB785D41F0_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_2055A8CE2779597686FA54727CA4DF0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_5A3B1F056BEACDAA3FC312EB785D41F0_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_2055A8CE2779597686FA54727CA4DF0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_2055A8CE2779597686FA54727CA4DF0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_2055A8CE2779597686FA54727CA4DF0D" xlink:to="lab_dei_LocalPhoneNumber_2055A8CE2779597686FA54727CA4DF0D" xlink:type="arc" />
    <link:label id="lab_dei_WrittenCommunications_DCE23CB8DE201B588EA312EB785DBCD6_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications_3CBC2CE7A9D1534EACC256311C985B7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_DCE23CB8DE201B588EA312EB785DBCD6_label_en-US" xlink:label="lab_dei_WrittenCommunications_3CBC2CE7A9D1534EACC256311C985B7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_3CBC2CE7A9D1534EACC256311C985B7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications_3CBC2CE7A9D1534EACC256311C985B7B" xlink:to="lab_dei_WrittenCommunications_3CBC2CE7A9D1534EACC256311C985B7B" xlink:type="arc" />
    <link:label id="lab_dei_SolicitingMaterial_760B757C59FA279516CD12EB785D2D23_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial_4660951B81F25E4787365D008771958A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_760B757C59FA279516CD12EB785D2D23_label_en-US" xlink:label="lab_dei_SolicitingMaterial_4660951B81F25E4787365D008771958A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_4660951B81F25E4787365D008771958A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial_4660951B81F25E4787365D008771958A" xlink:to="lab_dei_SolicitingMaterial_4660951B81F25E4787365D008771958A" xlink:type="arc" />
    <link:label id="lab_dei_PreCommencementTenderOffer_344CB19EC791150E96E912EB785DB49A_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer_D754825370C55AE884C79263CF2F71EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_344CB19EC791150E96E912EB785DB49A_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer_D754825370C55AE884C79263CF2F71EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_D754825370C55AE884C79263CF2F71EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer_D754825370C55AE884C79263CF2F71EE" xlink:to="lab_dei_PreCommencementTenderOffer_D754825370C55AE884C79263CF2F71EE" xlink:type="arc" />
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_59137A62338E67AAB28C12EB785D6654_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer_FD65F8E47A585899B52E32FEBC127033" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_59137A62338E67AAB28C12EB785D6654_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer_FD65F8E47A585899B52E32FEBC127033" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_FD65F8E47A585899B52E32FEBC127033" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer_FD65F8E47A585899B52E32FEBC127033" xlink:to="lab_dei_PreCommencementIssuerTenderOffer_FD65F8E47A585899B52E32FEBC127033" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_001777A8A6AF6538D2A412EB7859C521_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_235209D2C2FA58F286D84674A4E9BA04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_001777A8A6AF6538D2A412EB7859C521_label_en-US" xlink:label="lab_dei_Security12bTitle_235209D2C2FA58F286D84674A4E9BA04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_235209D2C2FA58F286D84674A4E9BA04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_235209D2C2FA58F286D84674A4E9BA04" xlink:to="lab_dei_Security12bTitle_235209D2C2FA58F286D84674A4E9BA04" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_B80EC5FA2E5A9146AE5012EB785D4F73_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_3CC8CBA5DB84519099584DB878398987" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_B80EC5FA2E5A9146AE5012EB785D4F73_label_en-US" xlink:label="lab_dei_TradingSymbol_3CC8CBA5DB84519099584DB878398987" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_3CC8CBA5DB84519099584DB878398987" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_3CC8CBA5DB84519099584DB878398987" xlink:to="lab_dei_TradingSymbol_3CC8CBA5DB84519099584DB878398987" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_BD2611354DB294EA551E12EB785E1FBF_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_DEA25E8E2D005848BBDE541464B1CB94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_BD2611354DB294EA551E12EB785E1FBF_label_en-US" xlink:label="lab_dei_SecurityExchangeName_DEA25E8E2D005848BBDE541464B1CB94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_DEA25E8E2D005848BBDE541464B1CB94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_DEA25E8E2D005848BBDE541464B1CB94" xlink:to="lab_dei_SecurityExchangeName_DEA25E8E2D005848BBDE541464B1CB94" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_273F49BF87E829DB473712EB785EE2F6_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_AB395692166F50199436164AB1C00CBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_273F49BF87E829DB473712EB785EE2F6_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_AB395692166F50199436164AB1C00CBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_AB395692166F50199436164AB1C00CBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_AB395692166F50199436164AB1C00CBD" xlink:to="lab_dei_EntityEmergingGrowthCompany_AB395692166F50199436164AB1C00CBD" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_FB2DC3B7252F22BA459212EB785B3EDD_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_D04DB365DA865199A768A13AC90DA909" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_FB2DC3B7252F22BA459212EB785B3EDD_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_D04DB365DA865199A768A13AC90DA909" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_D04DB365DA865199A768A13AC90DA909" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_D04DB365DA865199A768A13AC90DA909" xlink:to="lab_dei_EntityCentralIndexKey_D04DB365DA865199A768A13AC90DA909" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_32233D09D70BAE14723212EB785B60EE_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_882C496281E25AEE8AFB0381211CA918" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_32233D09D70BAE14723212EB785B60EE_label_en-US" xlink:label="lab_dei_AmendmentFlag_882C496281E25AEE8AFB0381211CA918" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_882C496281E25AEE8AFB0381211CA918" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_882C496281E25AEE8AFB0381211CA918" xlink:to="lab_dei_AmendmentFlag_882C496281E25AEE8AFB0381211CA918" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>ptct-20200805_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.ptcbio.com/role/CoverPageDocument" xlink:href="ptct-20200805.xsd#CoverPageDocument" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/CoverPageDocument" xlink:type="extended">
    <link:loc xlink:href="ptct-20200805.xsd#ptct_CoverpageAbstract" xlink:label="loc_ptct_CoverpageAbstract_F2AF802911AA504F9499C3278686FCED" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_9E7EE3083DD7584B8420EF40F0FF72BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_F2AF802911AA504F9499C3278686FCED" xlink:to="loc_dei_DocumentType_9E7EE3083DD7584B8420EF40F0FF72BC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_CE7C9F6A10D55E9CAC5927881326C3B3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_F2AF802911AA504F9499C3278686FCED" xlink:to="loc_dei_DocumentPeriodEndDate_CE7C9F6A10D55E9CAC5927881326C3B3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_F69AA206B4DC5E13868DF2306B48F46A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_F2AF802911AA504F9499C3278686FCED" xlink:to="loc_dei_EntityRegistrantName_F69AA206B4DC5E13868DF2306B48F46A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_771A8C419C8B5C9F997AFAD56B5220F2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_F2AF802911AA504F9499C3278686FCED" xlink:to="loc_dei_EntityIncorporationStateCountryCode_771A8C419C8B5C9F997AFAD56B5220F2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_8F5DE1156E095CA49AF970255BEA3766" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_F2AF802911AA504F9499C3278686FCED" xlink:to="loc_dei_EntityFileNumber_8F5DE1156E095CA49AF970255BEA3766" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_CBB8F09B97255FAE88614683DE811FCB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_F2AF802911AA504F9499C3278686FCED" xlink:to="loc_dei_EntityTaxIdentificationNumber_CBB8F09B97255FAE88614683DE811FCB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_A1DCE45656CB5EF69D32FA2BB8C3C9BA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_F2AF802911AA504F9499C3278686FCED" xlink:to="loc_dei_EntityAddressAddressLine1_A1DCE45656CB5EF69D32FA2BB8C3C9BA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_BBE78AB9F41A5CB09756FE0AF1F5C62E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_F2AF802911AA504F9499C3278686FCED" xlink:to="loc_dei_EntityAddressCityOrTown_BBE78AB9F41A5CB09756FE0AF1F5C62E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_3F350A39A7E556F184B683327E6B789A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_F2AF802911AA504F9499C3278686FCED" xlink:to="loc_dei_EntityAddressStateOrProvince_3F350A39A7E556F184B683327E6B789A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_9C7CB798F5DC511D8F1E93BBE1BF2874" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_F2AF802911AA504F9499C3278686FCED" xlink:to="loc_dei_EntityAddressPostalZipCode_9C7CB798F5DC511D8F1E93BBE1BF2874" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_087588155CA15C37B5540C9F7B6803F9" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_F2AF802911AA504F9499C3278686FCED" xlink:to="loc_dei_CityAreaCode_087588155CA15C37B5540C9F7B6803F9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_2055A8CE2779597686FA54727CA4DF0D" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_F2AF802911AA504F9499C3278686FCED" xlink:to="loc_dei_LocalPhoneNumber_2055A8CE2779597686FA54727CA4DF0D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_3CBC2CE7A9D1534EACC256311C985B7B" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_F2AF802911AA504F9499C3278686FCED" xlink:to="loc_dei_WrittenCommunications_3CBC2CE7A9D1534EACC256311C985B7B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_4660951B81F25E4787365D008771958A" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_F2AF802911AA504F9499C3278686FCED" xlink:to="loc_dei_SolicitingMaterial_4660951B81F25E4787365D008771958A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_D754825370C55AE884C79263CF2F71EE" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_F2AF802911AA504F9499C3278686FCED" xlink:to="loc_dei_PreCommencementTenderOffer_D754825370C55AE884C79263CF2F71EE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_FD65F8E47A585899B52E32FEBC127033" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_F2AF802911AA504F9499C3278686FCED" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_FD65F8E47A585899B52E32FEBC127033" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_235209D2C2FA58F286D84674A4E9BA04" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_F2AF802911AA504F9499C3278686FCED" xlink:to="loc_dei_Security12bTitle_235209D2C2FA58F286D84674A4E9BA04" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_3CC8CBA5DB84519099584DB878398987" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_F2AF802911AA504F9499C3278686FCED" xlink:to="loc_dei_TradingSymbol_3CC8CBA5DB84519099584DB878398987" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_DEA25E8E2D005848BBDE541464B1CB94" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_F2AF802911AA504F9499C3278686FCED" xlink:to="loc_dei_SecurityExchangeName_DEA25E8E2D005848BBDE541464B1CB94" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_AB395692166F50199436164AB1C00CBD" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_F2AF802911AA504F9499C3278686FCED" xlink:to="loc_dei_EntityEmergingGrowthCompany_AB395692166F50199436164AB1C00CBD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_D04DB365DA865199A768A13AC90DA909" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_F2AF802911AA504F9499C3278686FCED" xlink:to="loc_dei_EntityCentralIndexKey_D04DB365DA865199A768A13AC90DA909" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_882C496281E25AEE8AFB0381211CA918" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_F2AF802911AA504F9499C3278686FCED" xlink:to="loc_dei_AmendmentFlag_882C496281E25AEE8AFB0381211CA918" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ptctq2earningsrelease_image1.gif
<TEXT>
begin 644 ptctq2earningsrelease_image1.gif
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E,4455V2Q11=?A#%&&6>DL48;;\0Q1QUWY+%''W\$,DCZ @( .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>a8k8520_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ptct-20200805.xsd" xlink:type="simple"/>
    <context id="D2020Q3E">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <startDate>2020-08-05</startDate>
            <endDate>2020-08-05</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="D2020Q3E"
      id="Fact-4F979432D305596D913B7EBE8879AB76-wk-Fact-4F979432D305596D913B7EBE8879AB76">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="D2020Q3E"
      id="Fact-0D0EC0B070A95DF5B791286A427089C2-wk-Fact-0D0EC0B070A95DF5B791286A427089C2">0001070081</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="D2020Q3E"
      id="d13084735e67-wk-Fact-68499F752497548E85B143C712605F12">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="D2020Q3E"
      id="d13084735e81-wk-Fact-33EFA30D7C555A7DBAAA3718951FE2DE">2020-08-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="D2020Q3E"
      id="d13084735e86-wk-Fact-94A86FC750FE5F92BCB30AA98F234082">PTC THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="D2020Q3E"
      id="d13084735e110-wk-Fact-BB8366D61231524CAEDC7DBC8310A572">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="D2020Q3E"
      id="d13084735e120-wk-Fact-32E5B10931A651388AD71E73573CAC6C">001-35969</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="D2020Q3E"
      id="d13084735e130-wk-Fact-67611E6ECD225CD6AC00C60F0A34FC02">04-3416587</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="D2020Q3E"
      id="d13084735e182-wk-Fact-5057FCCA38D554CB97E84E8CBAE55E79">100 Corporate Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="D2020Q3E"
      id="d13084735e203-wk-Fact-97AB5057C3075063A87EC7385A15593C">South Plainfield,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="D2020Q3E"
      id="d13084735e208-wk-Fact-088FC68F16FE5B3A9468247F1DCBCFDE">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="D2020Q3E"
      id="d13084735e218-wk-Fact-D0F3DB3658265DD5AE4C5ADD58C49C8B">07080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="D2020Q3E"
      id="d13084735e245-wk-Fact-62A845CCE640584D8AA8006CC0285511">(908)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="D2020Q3E"
      id="d13084735e249-wk-Fact-5B92A3BBFF4E5E02BB6B6116F0079635">222-7000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="D2020Q3E"
      id="d13084735e270-wk-Fact-F89F470AF7EB57F59FB8DFC3F3743B3E">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="D2020Q3E"
      id="d13084735e280-wk-Fact-A9E59E4F8EF15CC884D91487C5D578E0">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="D2020Q3E"
      id="d13084735e290-wk-Fact-AF64783EB25350B38E09F4F55D4F4A8B">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="D2020Q3E"
      id="d13084735e300-wk-Fact-3CCF5084961553B8A911A2258BAF507B">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="D2020Q3E"
      id="d13084735e342-wk-Fact-3694E7541D0E5E5E9D7ED50ADD2285E0">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="D2020Q3E"
      id="d13084735e347-wk-Fact-917658A6465A54EBAA7FDEE6BB071639">PTCT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="D2020Q3E"
      id="d13084735e352-wk-Fact-E45F2088156C54848A32499CD123C127">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="D2020Q3E"
      id="d13084735e362-wk-Fact-0CD23217F7935AED8E15789DBA0D8BE0">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140198553346712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page Document<br></strong></div></th>
<th class="th"><div>Aug. 05, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_CoverpageAbstract', window );"><strong>cover page [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  05,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PTC THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Address, State or Province</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Contained File Information, File Number</a></td>
<td class="text">001-35969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3416587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Corporate Court<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South Plainfield,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(908)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">222-7000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PTCT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001070081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_CoverpageAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>cover page [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_CoverpageAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M[0OP/%;*'!OV/%K]G3#^!U!+ P04    " #%@ 51@ZFE ]0!   R!@  #0
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M2Z@P0/FFHE%Y;:O8<M(=O<[T_F'RJ*VTSJV4>P^O9,LQ\/A9RQ]02P,$%
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MO-9.&G_FB^$_7G\!4$L! A0#%     @ Q8 %40=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #%@ 51
MNSEOV>X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " #%@ 51F5R<(Q &  "<)P  $P              @ ',
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ,6 !5%PBX[22 0
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M2P$"% ,4    " #%@ 51)!Z;HJT   #X 0  &@              @ '9$
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #%@ 5199!Y
MDAD!  #/ P  $P              @ &^$0  6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     "0 ) #X"   ($P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="a8k8520.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover Page Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/CoverPageDocument</Role>
      <ShortName>Cover Page Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="a8k8520.htm">a8k8520.htm</File>
    <File>ptct-20200805.xsd</File>
    <File>ptct-20200805_cal.xml</File>
    <File>ptct-20200805_def.xml</File>
    <File>ptct-20200805_lab.xml</File>
    <File>ptct-20200805_pre.xml</File>
    <File>ptctq2earningsrelease8.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "a8k8520.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "calculationLink": {
     "local": [
      "ptct-20200805_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ptct-20200805_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "a8k8520.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ptct-20200805_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ptct-20200805_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ptct-20200805.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ptct",
   "nsuri": "http://www.ptcbio.com/20200805",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a8k8520.htm",
      "contextRef": "D2020Q3E",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover Page Document",
     "role": "http://www.ptcbio.com/role/CoverPageDocument",
     "shortName": "Cover Page Document",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a8k8520.htm",
      "contextRef": "D2020Q3E",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Contained File Information, File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "ptct_CoverpageAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "cover page [Abstract]",
        "label": "cover page [Abstract]"
       }
      }
     },
     "localname": "CoverpageAbstract",
     "nsuri": "http://www.ptcbio.com/20200805",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001070081-20-000127-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001070081-20-000127-xbrl.zip
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MD2?K[MF;SN&?F@_L!\9_?L]^EOSP_P%02P,$%     @ Q8 %498M^86H P
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M<WYA*IUTEUM9/-G>,-S[!U!+ P04    " #%@ 51+%IB"ST!  "  @  %0
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M\/LO/*C_[V8G(>@<J!+**#6F5_]@TOL$4$L#!!0    ( ,6 !5$S(+T=G@$
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M:,V)N#\X-4+[32.4"/?;Q$]WZL!UVEG?YH':@>+ 8Z8^.;I9AZUW4$L#!!0
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M.!^/RKKOB[*\^OGP\.;FYOWM:3%[GQ?GAP@ ?'C_4WN/J/XV6!\VJ-X:0#3
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MC2'O*?IF6%Z_V!OFSMM.B,?%_? 7>.Q??7RW?F>Z_!_*?'SW?U!+ P04
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M0TSJ"EK(*4TM:97,\_A$I;$WJ>]'H*9O)18^($_-LCCKC\U2_F )<*?#?FZ
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M')5.C(,WAS)@\5PE$0]<&&SQS1&+6!>T,Q"!']VRS^LZO+-_6Z)X@L1</AD
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M9.&)N6SC2#54D7W+()E\6UGR;69/DF%*>V "!C#* AAF3Y))T)<))4UZUFB
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M(K!E-W%B7(DG$:8J"5S=07HR#464 @A)(P,8J5!-DDA+!DH&3Y13"=U>R(5
M32.[#GD03?$,\YAP,9=(+_:'@)111,]1N7PI'L,G$WA<0P8-Q^/X ; ?>CK:
M7%@0?0[(PJ%U@+TD\$6L'P,S% CA-MFY8AY2%^8K&!Z>*9\%[@%I#+N0@"4L
MB:Y"'O52VS=^#]U\#],_4>JKA7^<PZ CE,%]_PT-OI7*TG(%[&<9?!7NAV _
MH.!I6,5[F+2/. 4?@E0C5/" [*$,(GY(76ST?*QH[(EO[)\<S \;^3\V\)76
M$/B*W6Z,^JOR]OOWBW^%QO][921&P_/I_PBXPY]OZO^!L_Z6_[YEYNW^X/N[
M]?N$_VXF?@>T7?+093^#:T F>!:# R=7=<R><9C.YQ)C$/2F:<R.L4+,94 N
M%+O<\-(N1WF7B4M(369\P3'D1U=^C@$"$ &XC)WEAY*#IXOE3'.%+P)QG8T=
MBDSLT:@',8/G%9M.'P\L@1X@\XZ!0X7GA<@W@N(-T!!<!9 J'3;E3@P>-A37
M=-Z"AATO<3=$"L4,KH</CS7!2>($FA'?L')0QT)(!X"K9#$9U11JHD%<8=6J
M9EJZZ# +[71#(%4L_72X,EH'M 7F)BL!@"8$/"H-DC0O@XOQA3,6=C*!R$R%
M2Q8EDY09Z3OQ>?![1IQHJ,"# ON(7JV)<:5[F@/.@#-B3X%M+U'0&&>J*!42
MV86*B7MZU_7$YT&"$P'S#[<Y?)%7.;QBW+W E_X00P2I]*-_5Q A,WHMS$2%
M6E-@@&<A]U$)SCZ.[]H/:QN1AK!6+;F'XXFLTD,_'&! O20->)7V)I\IH.S8
M1^B) RP19CH$OH=SR6>AT"+04'Y)6_U,Y'^]F1U#CJUXTA%!!!)=.ZU; P*D
M]CDC3]41_\"XWJ77*X$T^(Q4V38?K]E_IKH__C!LVX-7JR9OT!?*%$!@XVCC
MPS]/?OF?#Z<->P2#&;C"!TO4*NE1E)*I)F)%!%:5#W4$Y#\6,XB#4G-3"Q%F
MQI9^-)4!: Q.]4(!"X?O\J_2\PK0,$/UNYXT1T4H #X>.Z8FO^O*7^HJ:":?
MT<PUV2]D(==@G,^7F&*0>"J.#ELF2VKS$H8O8@>S!$8:=/G 8@<(#-8!.^!P
MJ2,A[A#XUP2"'.@B_HK)(3_]6 \N_H:)H<#%W^!A^"/FX4S05[F&XQ^8[J"?
M*O'H<B?[)9JO/H++833@=P(2F'F/ASB3B.XXI+6--"ATQS 7,(D@(TH\] .@
M;!1F8%H,3($[<YRNS W!N*;A-N*HP(8A+$Y!0$4B&UJ,ZT,T""_5D6MT"J)(
MGW]%C,8\@NX(*B9G%SR40D-]**.OVJP3Z%F(WC FG[#"0-V!S+YBI7T6A*T
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MKXB0.B0:NU67,0.OUXXV0P8+.]+(/UP%#]#XR<<3F&R(!Z(T3(*YAR:6%"&
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M,C N:'1M4$L! A0#%     @ Q8 %498M^86H P  71(  !$
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M4$L! A0#%     @ Q8 %47"_K0.B!@  =34  !4              ( !%RP
M '!T8W0M,C R,# X,#5?<')E+GAM;%!+ 0(4 Q0    ( ,6 !5%$X4,<]S(
M (SW @ :              "  >PR  !P=&-T<3)E87)N:6YG<W)E;&5A<V4X
:+FAT;5!+!08     !P ' ,P!   ;9@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
